|
1
|
Heidenreich A, Bellmunt J, Bolla M, Joniau
S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel
T, et al: EAU guidelines on prostate cancer. Part 1: Screening,
diagnosis, and treatment of clinically localised disease. Eur Urol.
59:61–71. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Briganti A, Blute ML, Eastham JH, Graefen
M, Heidenreich A, Karnes JR, Montorsi F and Studer UE: Pelvic lymph
node dissection in prostate cancer. Eur Urol. 55:1251–1265.
2009.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Van den Bergh L, Lerut E, Haustermans K,
Deroose CM, Oyen R, Isebaert S, Budiharto T, Ameye F, Mottaghy FM,
Bogaerts K, et al: Final analysis of a prospective trial on
functional imaging for nodal staging in patients with prostate
cancer at high risk for lymph node involvement. Urol Oncol.
33:109.e23–31. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hövels AM, Heesakkers RA, Adang EM, Jager
GJ, Strum S, Hoogeveen YL, Severens JL and Barentsz JO: The
diagnostic accuracy of CT and MRI in the staging of pelvic lymph
nodes in patients with prostate cancer: A meta-analysis. Clin
Radiol. 63:387–395. 2008.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Briganti A, Abdollah F, Nini A, Suardi N,
Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A,
et al: Performance characteristics of computed tomography in
detecting lymph node metastases in contemporary patients with
prostate cancer treated with extended pelvic lymph node dissection.
Eur Urol. 61:1132–1138. 2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
National Comprehensive Cancer Network:
Guidelines on prostate cancer. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
Accessed February 1, 2018.
|
|
7
|
European Association of Urology:
Guidelines on prostate cancer. https://uroweb.org/guideline/prostate-cancer/#6.
Accessed February 1, 2018.
|
|
8
|
Joslyn SA and Konety BR: Impact of extent
of lymphadenectomy on survival after radical prostatectomy for
prostate cancer. Urology. 68:121–125. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bader P, Burkhard FC, Markwalder R and
Studer UE: Disease progression and survival of patients with
positive lymph nodes after radical prostatectomy. Is there a chance
of cure? J Urol. 169:849–854. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Daneshmand S, Quek ML, Stein JP,
Lieskovsky G, Cai J, Pinski J, Skinner EC and Skinner DG: Prognosis
of patients with lymph node positive prostate cancer following
radical prostatectomy: Long-term results. J Urol. 172:2252–2255.
2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wagner M, Sokoloff M and Daneshmand S: The
role of pelvic lymphadenectomy for prostate cancer-therapeutic? J
Urol. 179:408–413. 2008.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fossati N, Willemse PM, Van den Broeck T,
van den Bergh RCN, Yuan CY, Briers E, Bellmunt J, Bolla M, Cornford
P, De Santis M, et al: The benefits and harms of different extents
of lymph node dissection during radical prostatectomy for prostate
cancer: A systematic review. Eur Urol. 72:84–109. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
D'Amico AV, Whittington R, Malkowicz SB,
Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA,
Kaplan I, Beard CJ and Wein A: Biochemical outcome after radical
prostatectomy, external beam radiation therapy, or interstitial
radiation therapy for clinically localized prostate cancer. JAMA.
280:969–974. 1998.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Sobin LH, Gospodarowicz MK and Wittekind
Ch: TNM Classification of Malignant Tumors. 7th edition. Wiley
Blackwell, Oxford. 2009.
|
|
15
|
Mitsuzuka K, Koie T, Narita S, Kaiho Y,
Yoneyama T, Kawamura S, Tochigi T, Ohyama C, Habuchi T and Arai Y:
Is pelvic lymph node dissection required at radical prostatectomy
for low-risk prostate cancer? Int J Urol. 20:1092–1096.
2013.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Pound CR, Partin AW, Eisenberger MA, Chan
DW, Pearson JD and Walsh PC: Natural history of progression after
PSA elevation following radical prostatectomy. JAMA. 281:1591–1597.
1999.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Makarov DV, Humphreys EB, Mangold LA,
Carducci MA, Partin AW, Eisenberger MA, Walsh PC and Trock BJ: The
natural history of men treated with deferred androgen deprivation
therapy in whom metastatic prostate cancer developed following
radical prostatectomy. J Urol. 179:156–162. 2008.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Heidenreich A, Bastian PJ, Bellmunt J,
Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T,
Zattoni F, et al: EAU guidelines on prostate cancer. Part 1:
Screening, diagnosis, and local treatment with curative
intent-update 2013. Eur Urol. 65:124–137. 2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Briganti A, Suardi N, Gallina A, Abdollah
F and Montorsi F: Pelvic lymph node dissection in prostate cancer:
The mystery is taking shape. Eur Urol. 63:459–461. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Prendeville S and van der Kwast TH: Lymph
node staging in prostate cancer: Perspective for the pathologist. J
Clin Pathol. 69:1039–1045. 2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Seiler R, Studer UE, Tschan K, Bader P and
Burkhard FC: Removal of limited nodal disease in patients
undergoing radical prostatectomy: Long-term results confirm a
chance for cure. J Urol. 191:1280–1285. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Yuen K, Miura T, Sakai I, Kiyosue A and
Yamashita M: Intraoperative fluorescence imaging for detection of
sentinel lymph nodes and lymphatic vessels during open
prostatectomy using indocyanine green. J Urol. 194:371–377.
2015.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Furubayashi N, Negishi T, Iwai H, Nagase
K, Taguchi K, Shimokawa M and Nakamura M: Determination of adequate
pelvic lymph node dissection range for Japanese males, undergoing
radical prostatectomy. Mol Clin Oncol. 6:775–781. 2017.PubMed/NCBI View Article : Google Scholar
|
